As oligo manufacturers scale up production from lab-scale to clinical and commercial scales, they may require volumes of hazardous materials that drive additional facility design considerations.
Kyle Hubbard
Advertisement
Kyle Hubbard is process engineer at CRB.
Articles by Kyle Hubbard
Advertisement
Latest Updated Articles
Oligonucleotide Production FacilitiesNovember 15th 2023
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5